EZH2 and Miyoshi myopathy: However, we and others have demonstrated that EZH2 overexpression is a common feature among MM patients and is associated with shorter survival, independent of established prognostic factors such as the International Staging System (ISS), GEP70 risk and cytogenetic classification6,13.